PHARMACEUTICAL COMPOSITION COMBINING AN ENZYME HMG-COA REDUCTASE INHIBITING AGENT AND A GASTROINTESTINAL LIPASE ENZYME INHIBITING AGENT.

摘要

The invention relates to a pharmaceutical composition comprising a synergic combination of an enzyme HMG-CoA reductase inhibiting agent, such as active principle atorvastatin, and a gastrointestinal lipase enzyme inhibiting agent, such as active principle orlistat, which are formulated in a single dosage unit intended to be administered orally for the treatment and control of diseases such as: dyslipemias (hypercholesterolemia and hypertriglyceridemia) and other related conditions.